ARA-290 (Cibinetide)

ARA-290, also known as Cibinetide, is an 11-amino acid cyclic peptide engineered by Araim Pharmaceuticals to selectively activate the "innate repair receptor" (IRR) - a heterodimeric receptor complex consisting of the erythropoietin receptor (EPOR) and the beta-common receptor (beta-c, also called CD131). This receptor complex mediates the tissue-protective effects of erythropoietin (EPO) but is distinct from the homodimeric EPOR that drives red blood cell production.

This distinction is the key innovation of ARA-290. Erythropoietin itself activates both receptor types - the haematopoietic EPOR homodimer that stimulates erythropoiesis, and the tissue-protective IRR heterodimer. While EPO has documented tissue-protective and anti-inflammatory properties, using it therapeutically to access those effects is complicated by the concurrent stimulation of red blood cell production, which raises the risk of polycythaemia, hypertension, and thromboembolism. ARA-290 was specifically engineered to bind only the IRR/EPOR-beta heterodimer, completely decoupling tissue protection from haematopoiesis.

The mechanism of IRR activation triggers an anti-apoptotic, anti-inflammatory intracellular cascade including PI3K/Akt and JAK2/STAT5 signalling. These pathways promote cellular survival under hypoxic and ischaemic conditions, reduce pro-inflammatory cytokine production, and stimulate repair processes in damaged tissue. ARA-290 essentially activates an endogenous stress-response pathway that EPO naturally engages but that can now be targeted without blood count side effects.

Clinical development has focused on peripheral neuropathy as the lead indication. A Phase 2 randomised controlled trial in patients with sarcoidosis-associated small fibre neuropathy showed statistically significant reductions in neuropathic pain scores after 28 days of 4 mg/day subcutaneous administration. This represented a meaningful clinical finding for a patient population with very limited treatment options.

Preclinical research has documented ARA-290's effectiveness across multiple models: ischaemia-reperfusion injury in kidney and heart, peripheral nerve regeneration (promoting axonal regrowth and Schwann cell migration), diabetic neuropathy (both structural nerve preservation and functional improvement), beta-cell protection in the context of islet transplantation, and traumatic brain injury.

The fact that ARA-290 lacks haematopoietic activity fundamentally changes the risk calculus for chronic administration compared to EPO, making it potentially suitable for long-term therapeutic use in degenerative conditions. Research continues across a range of conditions where tissue protection and anti-inflammatory activity are therapeutic objectives.